Linnaeus Therapeutics, Inc.
BiotechnologyOncology Therapeutics
Haddonfield, NJ
About
Linnaeus Therapeutics is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for oncology. The company's lead program targets the G protein-coupled estrogen receptor (GPER) to activate tumor-suppressive pathways, aiming to treat cancers like melanoma, particularly in patients who do not respond to existing immunotherapies.
Company Values
The company's approach is rooted in discoveries from the University of Pennsylvania, targeting the GPER receptor which is a novel mechanism in oncology. This strategy is coupled with a predictive biomarker to identify patients most likely to benefit, addressing a significant unmet need for those intolerant to traditional immunotherapy.